Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | HPGD | P15428 | 4/20 | 0.60 |
| ▸ | GAA | P10253 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27344271 | 0.86 | ALDH1A1 (0.64) | KDM4EALDH1A1HPGDGAAMAPT | |
| SCHEMBL6311629 | 0.86 | MAPT (0.66) | KDM4EALDH1A1HPGDMAPTLMNA | |
| SCHEMBL11384176 | 0.85 | KDM4E (0.57) | KDM4EALDH1A1HPGDGAAMAPT | |
| SCHEMBL3373937 | 0.83 | ALDH1A1 (0.55) | KDM4EALDH1A1HPGDGAAMAPT | |
| SCHEMBL14087050 | 0.83 | KDM4E (0.67) | KDM4EALDH1A1HPGDGAAMAPT | |
| SCHEMBL1422234 | 0.83 | LMNA (0.74) | KDM4EALDH1A1HPGDGAAMAPT | |
| SCHEMBL5017463 | 0.82 | LMNA (0.61) | KDM4EALDH1A1HPGDMAPTLMNA | |
| SCHEMBL5285087 | 0.82 | ALDH1A1 (0.57) | KDM4EALDH1A1HPGDGAAMAPT | |
| SCHEMBL12851276 | 0.82 | KDM4E (0.74) | KDM4EALDH1A1HPGDGAAMAPT | |
| SCHEMBL7368584 | 0.81 | HSD17B10 (0.53) | KDM4EALDH1A1MAPTLMNANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1896434-B1 | SUBSTITUTED HETEROARYL AMIDE MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NFkB ACTIVITY AND USE THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2011-02-23 | — | — | EP | disclosed |
| US-7495020-B2 | 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders | MERCK & CO., INC. (US) | 2009-02-24 | — | — | US | disclosed |
| US-7495020-B2 | 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders | MERCK & CO., INC. (US) | 2009-02-24 | — | — | US | disclosed |
| US-7361654-B2 | Substituted heteroaryl amide modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB CO. (US) | 2008-04-22 | — | — | US | disclosed |
| EP-1896434-A1 | SUBSTITUTED HETEROARYL AMIDE MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NFkB ACTIVITY AND USE THEREOF | Bristol-Myers Squibb Pharma Company (US) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006076632-A1 | SUBSTITUTED HETEROARYL AMIDE MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NFκB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-07-20 | — | — | WO | disclosed |
| US-20060154973-A1 | Substituted heteroaryl amide modulators of glucocorticoid receptor, AP-1, and/or NF-kB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154973-A1 | Substituted heteroaryl amide modulators of glucocorticoid receptor, AP-1, and/or NF-kB activity and use thereof | NFRKB, NFKB2, NFKB1 | KDM4E 2102/4885ALDH1A1 4114/4885HPGD 3595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.